Moleculin Enters Agreement with BSP Pharmaceuticals for its Leukemia Drug Candidate
Moleculin Biotech (NASDAQ: MBRX) a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, announced that it has entered into an agreement to expand production capability for Annamycin. As quoted in … Continued
Moleculin Biotech (NASDAQ: MBRX) a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, announced that it has entered into an agreement to expand production capability for Annamycin.
As quoted in the press release:
Moleculin has engaged BSP Pharmaceuticals S.p.A. (www.bsppharmaceuticals.com) in Latina, Italy to begin preparations for commercial scale production of Annamycin drug product.
“With the Phase I/II clinical trial of Annamycin now under way, we are taking the necessary steps to prepare for the commercial scale production of Annamycin,” commented Walter Klemp, Chairman and CEO of Moleculin. “BSP has a solid track record for supplying liposomal formulations to large pharmaceutical companies and their capabilities are a good match for us. We believe this partnership will assist us to take Annamycin to the next level.”
Mr. Aldo Braca, CEO of BSP Pharmaceuticals, added, “We see the potential for Annamycin to become a game-changer in the acute leukemia space, so we are pleased to be working with Moleculin.”
